Medytox is currently exporting products to approximately 60 countries including Japan and Brazil. In addition, we are striving to penetrate the market in the US and European countries in the near future. Based on these results, Medytox will show the status as a global leading biopharmaceutical company.
Thailand
Medytox Thailand
MedyCeles
Japan
MDT International, Tokyo
South Korea
서울본사
China
Medybloom China
Taiwan
Medytox Taiwan
HongKong
Medytox Hong Kong
US
Maryland
RU/CIS/Europe: 7
Kazakhstan, Uzbekistan, Russia, Ukraine, Moldova, Azerbaijan, Georgia
Asia/Middle East: 9
Korea, Philippines, Mongolia, Malaysia, Taiwan, India, Hongkong, lebanon, Saudi Arabia
America: 13
Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Guatemala, Mexico, Paraguay, Peru, El Salvador, Panama, Trinidad and Tobago
Asia/Middle East: 12
Korea, Philippines, Mongolia, Malaysia, Taiwan, Vietnam, Myanmar, Thailand, Singapore, Indonesia, Oman, Jordan
America: 12
Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Guatemala, Mexico, Paraguay, Peru, El Salvador, Ecuador
Oceania: 1
New Zealand
RU/CIS/Europe: 11
Kazakhstan, Uzbekistan, Russia, Ukraine, Moldova, Azerbaijan, Georgia, Turkey, United Kingdom, Kyrgyztan, CE
Starting from a Taiwan joint venture "Medytox Taiwan", Medytox established a China joint venture "Medybloom China",
a Hong Kong joint venture "Medytox Hong Kong", a Thailand joint venture "MedyCeles",
and 100% owned local subsidiaries in Japan and Thailand.
Medytox
Domestic Corporation Business
China joint venture
Taiwan joint venture
Hong Kong joint venture
Thailand joint venture
Thailand subsidiary
Japan subsidiary